{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.66","value":"-3.2"},{"groupId":"OG001","spread":"19.18","value":"-2.6"}]}],"title":"Week 6, n=243, 110"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.16","value":"-3.6"},{"groupId":"OG001","spread":"17.55","value":"-0.5"}]}],"title":"Week 12, n=219, 81"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.70","value":"-2.5"},{"groupId":"OG001","spread":"18.13","value":"-0.3"}]}],"title":"Week 18, n=191, 61"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.81","value":"0.1"},{"groupId":"OG001","spread":"18.67","value":"-0.5"}]}],"title":"Week 24, n=164, 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.36","value":"-0.3"},{"groupId":"OG001","spread":"15.63","value":"0.3"}]}],"title":"Week 48, n=96, 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer participants. The analyses for EORTC QLQ-C30 were focused on global health status/Health-Related Quality of Life (HRQOL) scores on the questionnaire. The scores (from 1 \\[very poor quality of life\\] to 7 \\[excellent quality of life\\]) for these two questions were averaged and then transformed to a 0 - 100 scale (based on published methods) prior to analysis of change from Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib"},{"description":"Matching placebo administered orally once a day","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Population who completed HRQOL assessments at Baseline and had at least one post-Baseline assessment are included. Only participants who were on treatment at the given time point were asked to complete the questionnaire, and only those who completed the questionnaire could be analyzed for each individual time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 6, 12, 18, 24, and 48","title":"Adjusted Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ C-30) Score at Weeks 6, 12, 18, 24, and 48","type":"SECONDARY","unitOfMeasure":"points on a scale"}